Abstract
CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to understand the cellular mechanisms by which they act. Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future.
Original language | English (US) |
---|---|
Pages (from-to) | 9-20 |
Number of pages | 12 |
Journal | Cancer Cell |
Volume | 34 |
Issue number | 1 |
DOIs | |
State | Published - Jul 9 2018 |
Keywords
- CDK4/6 inhibitors
- abemaciclib
- metabolism
- palbociclib
- ribociclib
- senescence
- tumor microenvironment
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research